Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

US10669589B2 · kind B2 · utility

Assignees

• The General Hospital Corporation · US
• DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

• Daphne Winifred Bell · Bethesda, US
• Daniel A. Haber · Sharon, US
• Pasi Janne · Needham, US
• Bruce E. Johnson · Bellevue, US
• Thomas J. Lynch · Cheverly, US
• Matthew Meyerson · Concord, US
• Juan Guillermo Paez · Deán Funes, AR
• William R. Sellers · Sharon, US
• Jeffrey E. Settleman · Newton, US
• Raffaella Sordella · Cold Spring Harbor, US

Key dates

• Filing date: May 16, 2018
• Grant date: Jun 2, 2020
• Expiry date: May 16, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.